ACKNOWLEDGMENTS
We would like to thank all of the investigators, staffs, all of the subjects and their families for their support in completing this trial during the outbreak of the COVID-19 pandemic. We thank Jiayang Song for carefully analyzing and reviewing the data and also appreciate Wen Jia, Peng Xia, and Chaonan Jin for providing help with manuscript preparation.This study was funded by the Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Guarantors of the article: S.W.Y. Specific author contributions: Study conception and design: X.Y.L.; B.J.W.; S.W.Y. Acquisition of data: the ibrexafungerp (HS-10366 in China) Study Group; Statistical analysis: J.Y.S.; Interpretation of the data and drafting of the manuscript: X.Y.L., P.X.; Critical revision of the manuscript for important intellectual content: all authors.